Trial
NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Advanced Malignant Solid Neoplasm
Intervention
Everolimus
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22